Literature DB >> 2285686

Therapeutic outcome of patients suffering from malignant melanomas of the conjunctiva.

P K Lommatzsch1, R E Lommatzsch, I Kirsch, P Fuhrmann.   

Abstract

Eighty-one cases of conjunctival melanoma treated between 1960 and 1988 were studied to determine factors that might affect outcome in patients with such lesions. The therapeutic procedures performed were local excision (16), local excision followed by brachytherapy with Sr-90/Y-90 (32), local excision followed by cryotherapy with liquid nitrogen (16), brachytherapy with Sr-90/Y-90 (12), local excision followed by external beam irradiation (3), and local excision followed by brachytherapy and cryotherapy (2). The median follow-up period was 5.5 years (longest 26, shortest 1 year). Sixty two patients (76.5%) showed a complete regression of the melanoma, 19 (23.5%) developed recurrences, and 15 (18.5%) died from metastases. The melanomas had developed with almost equal frequency from a pre-existing naevus (25.9%), from primary acquired melanosis (25.9%), and 'de novo' (30.9%). Small tumours had a higher chance of regressing (80.6%) than larger ones (68.6%). The cumulative survival rate was 76% after five years and 60% after 10 years from any causes of death and 87.6% after five years and 76.3% after 10 years from deaths caused by metastases. Most deaths from metastases occurred within 5 years. At 88.5%, the cumulative survival rate of patients with small tumours (less than one quadrant of the bulbar conjunctiva and less than 2 mm thickness) was significantly higher than that of patients with larger tumours (more than one quadrant of the bulbar conjunctiva and/or more than 2 mm thickness) with 65% after eight years. Local excision followed by beta ray irradiation (Sr-90/Y-90) or cryotherapy can be recommended as the treatment of choice. Nevertheless the behaviour of conjunctival melanomas remains unpredictable in individual cases.

Entities:  

Mesh:

Year:  1990        PMID: 2285686      PMCID: PMC1042232          DOI: 10.1136/bjo.74.10.615

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  11 in total

1.  Radiotherapy of malignant melanomata of the eye.

Authors:  M LEDERMAN
Journal:  Br J Radiol       Date:  1961-01       Impact factor: 3.039

2.  [Malignant epibulbar melanoma].

Authors:  G NOTTER
Journal:  Strahlentherapie       Date:  1955-04

3.  Beta irradiation of conjunctival melanomas.

Authors:  P K Lommatzsch
Journal:  Trans Ophthalmol Soc U K       Date:  1977-09

Review 4.  Conjunctival melanoma.

Authors:  F A Jakobiec
Journal:  Arch Ophthalmol       Date:  1980-08

5.  beta-Ray treatment of malignant epibulbar melanoma.

Authors:  P K Lommatzsch
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1978-12-15

6.  A prognostic index for patients with malignant melanoma of the conjunctiva.

Authors:  F H Stefani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

7.  Malignant melanoma of the conjunctiva.

Authors:  R Folberg; I W McLean; L E Zimmerman
Journal:  Hum Pathol       Date:  1985-02       Impact factor: 3.466

8.  [Survival after treatment for malignant choroidal melanoma: comparison between conservative therapy (Ru106/Rh106 applicator) and enucleation with and without postoperative irradiation to the orbit; 1960 to 1979].

Authors:  H Kiehl; I Kirsch; P Lommatzsch
Journal:  Klin Monbl Augenheilkd       Date:  1984-01       Impact factor: 0.700

9.  beta-Irradiation of choroidal melanoma with 106Ru/106Rh applicators. 16 Years' experience.

Authors:  P K Lommatzsch
Journal:  Arch Ophthalmol       Date:  1983-05

10.  Prognosis of conjunctival melanomas in relation to histopathological features.

Authors:  U Fuchs; T Kivelä; K Liesto; A Tarkkanen
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

View more
  19 in total

1.  Management of conjunctival malignant melanoma: a review and update.

Authors:  James R Wong; Afshan A Nanji; Anat Galor; Carol L Karp
Journal:  Expert Rev Ophthalmol       Date:  2014-06

2.  Amniotic membrane transplantation for reconstruction after excision of large ocular surface neoplasias.

Authors:  E M Espana; P Prabhasawat; M Grueterich; A Solomon; S C G Tseng
Journal:  Br J Ophthalmol       Date:  2002-06       Impact factor: 4.638

3.  Proton radiotherapy as an alternative to exenteration in the management of extended conjunctival melanoma.

Authors:  Henrike Wuestemeyer; Wolfgang Sauerwein; Daniel Meller; Pierre Chauvel; Andreas Schueler; Klaus-Peter Steuhl; Norbert Bornfeld; Gerasimos Anastassiou
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-08-23       Impact factor: 3.117

4.  Malignant melanoma of the conjunctiva: occurrence and survival following surgery and radiotherapy in a Danish population.

Authors:  J C Norregaard; N Gerner; O A Jensen; J U Prause
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-09       Impact factor: 3.117

5.  Conjunctival melanoma.

Authors:  A B Tullo; R Bonshek
Journal:  Br J Ophthalmol       Date:  1994-07       Impact factor: 4.638

Review 6.  Conjunctival Melanoma - Epidemiological Trends and Features.

Authors:  Snježana Kaštelan; Antonela Gverović Antunica; Lidija Beketić Orešković; Jasminka Salopek Rabatić; Boris Kasun; Ivana Bakija
Journal:  Pathol Oncol Res       Date:  2018-05-25       Impact factor: 3.201

Review 7.  Rare variants of malignant melanoma.

Authors:  G W Milton; H M Shaw
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

8.  Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia.

Authors:  P T Finger; G Czechonska; S Liarikos
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

9.  Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases.

Authors:  A D Paridaens; D C Minassian; A C McCartney; J L Hungerford
Journal:  Br J Ophthalmol       Date:  1994-04       Impact factor: 4.638

10.  Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma: a review of 68 cases.

Authors:  P De Potter; C L Shields; J A Shields; H Menduke
Journal:  Br J Ophthalmol       Date:  1993-10       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.